Eagle Plains Reports up to 427g/t Au at the Pine Channel Gold Project, Saskatchewan

CRANBROOK, BRITISH COLUMBIA / ACCESS Newswire / January 15, 2026 / Eagle Plains Resources Ltd. (TSXV:EPL)(OTCQB:EGPLF) ...
The Register on MSN

How one developer used Claude to build a memory-safe extension of C

Robin Rowe talks about coding, programming education, and China in the age of AI feature TrapC, a memory-safe version of the ...

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

The newly established CAB has been formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The CAB ...
Durham Region

‘Unable to function’: Driver with breath sample nearly 6 times legal limit among 15 charged with drunk driving in 3rd week of Durham RIDE program, say police

Durham police took a driver to the hospital after they blew nearly six times the legal limit — one of 15 people charged with impaired driving during the third week of a holiday RIDE program. “Officers ...
Seeking Alpha

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Yahoo Finance

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Seeking Alpha

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...